Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry

Journal of Mass Spectrometry

Volumn 43, Issue 2, 2008, Pages 216-223

  Marangon, Elena ^a   Sala, Federica ^a   Caffo, Orazio ^b   Galligioni, Enzo ^b   D'Incalci, Maurizio ^a   Zucchetti, Massimo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Gemcitabine; HPLC MS MS; Human pharmacokinetics; Non small cell lung cancer

Indexed keywords

LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PATIENT MONITORING; PULMONARY DISEASES; TUMORS;

GEMCITABINE; HUMAN PHARMACOKINETICS; NON-SMALL-CELL LUNG CANCER; TANDEM MASS SPECTROMETRY;

PHARMACOKINETICS;

CISPLATIN; DEOXYCYTIDINE; DRUG METABOLITE; GEMCITABINE;

ARTICLE; DIAGNOSTIC ACCURACY; DRUG ACTIVATION; DRUG DETERMINATION; DRUG ELIMINATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG NON SMALL CELL CANCER; PRECIPITATION; PRIORITY JOURNAL; STANDARD; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; VALIDATION PROCESS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; DEOXYCYTIDINE; FLOXURIDINE; HUMANS; LUNG NEOPLASMS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 39749135507     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1293     Document Type: Article

References (19)

1. Erlichman C. Novel chemotherapeutic agents in clinical development. Current Opinion in Oncology 1991; 3: 1037.
2. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowsky R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. Journal of Clinical Oncology 2006; 24: 3946.
3. Pectasides D, Pectasides M, Economopoulos T. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer. Cancer Treatment Reviews 2006; 32: 456.
4. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. Journal of Clinical Oncology 2003; 21: 3909.
5. Smith IE. Overview of gemcitabine activity in advanced breast cancer. Seminars in Oncology 2006; 33: S19.
6. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese JL. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. Journal of Clinical Oncology 2003; 21: 3402.
7. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. Journal of Clinical Oncology 1991; 9: 491.
8. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemotherapy and Pharmacology 1991; 27: 258.
9. Johnson SA. Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. Clinical Pharmacokinetics 2000; 39: 5.
10. Hochster HS. Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents. International Journal of Radiation Oncology, Biology, Physics 2003; 56: 24.
11. Santini D, Virzi V, Vincenzi B, Rocci L, Leoni V, Tonini G. A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients. Annals of Oncology 2007; 18: 576.
12. Wang L, Wu X, Huang M, Cai J, Xu N, Liu J. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 2007; 60: 211.
13. Freeman KB, Anliker S, Hamilton M, Osborne D, Dhahir PH, Nelson R, Allerheiligen SR. Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography. B, Biomedical Applications 1995; 665: 171.
14. Keith B, Xu Y, Grem JL. Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2003; 785: 65.
15. Kirstein MN, Hassan I, Guire DE, Weller DR, Dagit JW, Fisher JE, Remmel RP. High-performance liquid chromatographic method for the determination of gemcitabine and 2′,2′-difluorodeoxyuridine in plasma and tissue culture media. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2006; 835: 136.
16. Yilmaz B, Kadioglu YY, Aksoy Y. Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2003; 791: 103.
17. Lin NM, Zeng S, Ma SL, Fan Y, Zhong HJ, Fang L. Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector. Acta Pharmacologica Sinica 2004; 25: 1584.
18. Wang LZ, Goh BC, Lee HS, Noordhuis P, Peters GJ. An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography. Therapeutic Drug Monitoring 2003; 25: 552.
19. Honeywell R, Laan AC, van Groeningen CJ, Strocchi E, Ruiter R, Giaccone G, Peters GJ. The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2007; 847: 142.